Nephrolithiasis - Kidney Stone

Diagnostic Algorithm

Clinical Background

Nephrolithiasis is a worldwide problem that accounts for significant morbidity and expense.

Epidemiology

  • Prevalence – 1-5/1,000
  • Age – peaks in 20s
  • Sex – M>F, 2-3:1
  • Ethnicity – Caucasian men have highest incidence
  • Geographic – hotter and drier climates

Pathophysiology

  • Calcium oxalate/calcium phosphate stones are the most common (70-90%)
    • Risk factors include dehydration, thiazide diuretics, increased intestinal absorption, excessive oxalate consumption, pregnancy, primary hyperparathyroidism, chronic bowel malabsorption and chronic use of calcium-containing products
  • Magnesium ammonium phosphate stones (10-15%)
    • Risk factors include frequent urinary tract infections and presence of alkaline urine
    • Also referred to as struvite stones (staghorn calculi)
  • Uric acid stones (5-15%)
    • Risk factors include gout, family history, malignancy treated with chemotherapy, and high purine diet
  • Cystine stones (1-2%)
    • Risk factor is hereditary cystinuria

Clinical Presentation

  • Acute, colicky flank pain radiating into the pelvis and genitals associated with nausea and vomiting
  • Urinary urgency, frequency and dysuria may develop with stone passage
  • Hematuria is present in 90% of patients

Prevention

  • All stones – maintain urine volume ≥2 L/24-hours
  • Uric acid stones – limit protein intake
  • Cystine stones – limit protein and salt intake
  • Calcium stones
    • Citrate supplementation if urine citrate is low
    • Restrict high oxalate foods
    • Restrict salt and protein intake

Diagnosis

Indications for Testing

  • Patient with symptoms of a stone

Laboratory Testing

  • Initial testing
    • Urine – urinalysis for hematuria, bacteria
    • CBC – rule out concomitant infection
    • Electrolytes – rule out electrolyte abnormalities associated with vomiting
    • BUN/creatinine – rule out obstructive pathology
  • Urine – kidney stone risk assessment on 24-hour urine (this risk assessment may be delayed until recurrent stone disease occurs); initial testing should include 2 different specimens
    • Amino acids analysis – rule out cystinuria
  • Serum – uric acid, ionized calcium and parathyroid hormone-related peptide (PTH)
    • PTH may be reserved for recurrent disease
  • Stone – calculi analysis

Imaging Studies

  • Helical CT scan can confirm presence and location of stones

Differential Diagnosis

  • Peritonitis
  • Pyelonephritis
  • Ovarian torsion
  • Ovarian cyst
  • Ectopic pregnancy
  • Prostatitis
  • Musculoskeletal pain

Screening

  • No evidence to support screening for stones in asymptomatic patients

Monitoring

  • Unnecessary in first-time stone former
  • Usually includes:
    • Assessment 4-8 weeks after treatment
    • Urine – kidney stone risk assessment
      • Should include testing for calcium oxalate sodium, uric acid, citric acid, phosphorus, creatinine
      • Quantitative cystine in patients with cystinuria
    • Serum – urea nitrogen, creatinine and ionized calcium

Indications for Laboratory Testing

  • Tests generally appear in the order most useful for common clinical situations
  • Click on number for test-specific information in the ARUP Laboratory Test Directory
Test Name and Number Recommended Use Limitations Follow Up
CBC with Platelet Count & Automated Differential 0040003
Method: Automated Cell Count with Flow Cell Differential

Rule out concomitant infection

   
Electrolyte Panel 0020410
Method: Ion-Selective Electrode/Enzymatic

Rule out electrolyte abnormalities associated with vomiting

   
Urinalysis, Complete 0020350
Method: Reflective Photometry/Microscopic by Yellow IRIS
Detect urinary tract abnormalities including crystals    
Urine Supersaturation Profile 0081145
Method: pH Meter/Spectrophotometry/Ion-Selective Electrode/Enzymatic

Profile tests for calcium, magnesium, sodium, sulfate, citric acid, oxalate, uric acid, potassium, creatinine (24-hour) chloride and phosphorous

Predict formation of calcium oxalate, calcium hydrogen phosphate and/or uric acid calculi

Monitor renal stone disease after initiation of therapy

Assessment for risk of magnesium ammonium phosphate (struvite) calculi is not included in this profile

Does not test for urine cystine

If magnesium ammonium phosphate calculi are suspected, order plasma ammonia testing

If cystine calculi are suspected, order cystinuria panel, cystine quantitative urine or amino acids quantitative urine tests

Cystinuria Panel 0081105
Method: Ion Exchange Chromatography
Tests for arginine, cystine, lysine and ornithine    
Cystine Quantitative, Urine 0081106
Method:  Liquid Chromatography/Tandem Mass Spectrometry
Monitor treatment in patients with cystinuria
   
Amino Acids Quantitative, Urine 0080044
Method: Ion Exchange Chromatography

Use for risk assessment if cystine stone is found

   
Calculi (Stone) Analysis 0099460
Method: Reflectance Fourier Transform Infrared Spectroscopy (FTIR)/Polarizing Microscopy

Determine composition of calculi

Determine causative agent of calculi

   
Additional Tests Available
 
Click the plus sign to expand the table of additional tests.
Test Name and NumberComments
Kidney Stone Risk Panel, Urine 0020843
Method: Refer to individual components

Preferred test is urine supersaturation profile

Kidney Stone Risk Panel II, Urine 0020805
Method: Refer to individual components

Tests for calcium, chloride, citric acid, cystine, magnesium, oxalate, phosphorous, potassium, sodium

Creatinine, Serum or Plasma 0020025
Method: Spectrophotometry
Creatinine, 24-Hour Urine 0020473
Method: Spectrophotometry
Oxalate, Urine 0020482
Method: Spectrophotometry
Citric Acid, Urine 0020852
Method: Enzymatic
Urea Nitrogen, Serum or Plasma 0020023
Method: Spectrophotometry
Uric Acid, Serum or Plasma 0020026
Method: Spectrophotometry
Calcium, Ionized, Serum 0020135
Method: Ion-Selective Electrode/pH-Electrode
Parathyroid Hormone-Related Peptide (PTHrP) 0093014
Method: Immunoradiometric Assay